Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues
Standard
Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. / Kind, Simon; Merenkow, Christina; Büscheck, Franziska; Möller, Katharina; Dum, David; Chirico, Viktoria; Luebke, Andreas M; Höflmayer, Doris; Hinsch, Andrea; Jacobsen, Frank; Göbel, Cosima; Weidemann, Sören; Fraune, Christoph; Möller-Koop, Christina; Hube-Magg, Claudia; Clauditz, Till S; Simon, Ronald; Sauter, Guido; Wilczak, Waldemar; Bawahab, Ahmed Abdulwahab; Izbicki, Jakob R; Perez, Daniel; Marx, Andreas.
In: DIS MARKERS, Vol. 2019, 4928315, 2019.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues
AU - Kind, Simon
AU - Merenkow, Christina
AU - Büscheck, Franziska
AU - Möller, Katharina
AU - Dum, David
AU - Chirico, Viktoria
AU - Luebke, Andreas M
AU - Höflmayer, Doris
AU - Hinsch, Andrea
AU - Jacobsen, Frank
AU - Göbel, Cosima
AU - Weidemann, Sören
AU - Fraune, Christoph
AU - Möller-Koop, Christina
AU - Hube-Magg, Claudia
AU - Clauditz, Till S
AU - Simon, Ronald
AU - Sauter, Guido
AU - Wilczak, Waldemar
AU - Bawahab, Ahmed Abdulwahab
AU - Izbicki, Jakob R
AU - Perez, Daniel
AU - Marx, Andreas
N1 - Copyright © 2019 Simon Kind et al.
PY - 2019
Y1 - 2019
N2 - Syndecan-1 (CD138) is a transmembrane proteoglycan known to be expressed in various normal and malignant tissues. It is of interest because of a possible prognostic role of differential expression in tumors and its role as a target for indatuximab, a monoclonal antibody coupled with a cytotoxic agent. To comprehensively analyze CD138 in normal and neoplastic tissues, we used tissue microarrays (TMAs) for analyzing immunohistochemically detectable CD138 expression in 2,518 tissue samples from 85 different tumor entities and 76 different normal tissue types. The data showed that CD138 expression is abundant in tumors. At least an occasional weak CD138 immunostaining could be detected in 71 of 82 (87%) different tumor types, and 58 entities (71%) had at least one tumor with a strong positivity. In normal tissues, a particularly strong expression was found in normal squamous epithelium of various organs, goblet and columnar cells of the gastrointestinal tract, and in hepatocytes. The highly standardized analysis of most human cancer types resulted in a ranking order of tumors according to the frequency and levels of CD138 expression. CD138 immunostaining was highest in squamous cell carcinomas such as from the esophagus (100%), cervix uteri (79.5%), lung (85.7%), vagina (89.7%) or vulva (73.3%), and in invasive urothelial cancer (76.2%). In adenocarcinomas, CD138 was also high in lung (82.9%) and colorectal cancer (85.3%) but often lower in pancreas (73.3%), stomach (54.2% in intestinal type), or prostate carcinomas (16.3%). CD138 expression was usually low or absent in germ cell tumors, sarcomas, endocrine tumors including thyroid cancer, and neuroendocrine tumors. In summary, the preferential expression in squamous cell carcinomas of various sites makes these cancers prime targets for anti-CD138 treatments once these might become available. Abundant expression in many different normal tissues might pose obstacles to exploiting CD138 as a therapeutic target, however.
AB - Syndecan-1 (CD138) is a transmembrane proteoglycan known to be expressed in various normal and malignant tissues. It is of interest because of a possible prognostic role of differential expression in tumors and its role as a target for indatuximab, a monoclonal antibody coupled with a cytotoxic agent. To comprehensively analyze CD138 in normal and neoplastic tissues, we used tissue microarrays (TMAs) for analyzing immunohistochemically detectable CD138 expression in 2,518 tissue samples from 85 different tumor entities and 76 different normal tissue types. The data showed that CD138 expression is abundant in tumors. At least an occasional weak CD138 immunostaining could be detected in 71 of 82 (87%) different tumor types, and 58 entities (71%) had at least one tumor with a strong positivity. In normal tissues, a particularly strong expression was found in normal squamous epithelium of various organs, goblet and columnar cells of the gastrointestinal tract, and in hepatocytes. The highly standardized analysis of most human cancer types resulted in a ranking order of tumors according to the frequency and levels of CD138 expression. CD138 immunostaining was highest in squamous cell carcinomas such as from the esophagus (100%), cervix uteri (79.5%), lung (85.7%), vagina (89.7%) or vulva (73.3%), and in invasive urothelial cancer (76.2%). In adenocarcinomas, CD138 was also high in lung (82.9%) and colorectal cancer (85.3%) but often lower in pancreas (73.3%), stomach (54.2% in intestinal type), or prostate carcinomas (16.3%). CD138 expression was usually low or absent in germ cell tumors, sarcomas, endocrine tumors including thyroid cancer, and neuroendocrine tumors. In summary, the preferential expression in squamous cell carcinomas of various sites makes these cancers prime targets for anti-CD138 treatments once these might become available. Abundant expression in many different normal tissues might pose obstacles to exploiting CD138 as a therapeutic target, however.
U2 - 10.1155/2019/4928315
DO - 10.1155/2019/4928315
M3 - SCORING: Journal article
C2 - 31976021
VL - 2019
JO - DIS MARKERS
JF - DIS MARKERS
SN - 0278-0240
M1 - 4928315
ER -
